Related Experiment Video
Updated: Jun 16, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol
Florianne Bauer1, N Charlotte Onland-Moret, Onland-Moret N Charlotte
1Department of Medical Genetics-DBG, Complex Genetics Section, University Medical Center Utrecht, Utrecht, The Netherlands.
Summary
Genetic variations in the protein tyrosine phosphatase nonreceptor type 1 (PTPN1) gene are linked to cholesterol levels. Specific PTPN1 SNPs were associated with higher total and LDL cholesterol in leaner men.
Area of Science:
- Genetics and Molecular Biology
- Metabolic Disorders
- Cardiovascular Health
Background:
- The protein tyrosine phosphatase nonreceptor type 1 (PTPN1) gene encodes protein tyrosine phosphatase 1B, a key regulator of insulin signaling.
- PTPN1 variations may influence insulin sensitivity and contribute to metabolic endophenotypes.
- Understanding the genetic basis of metabolic health is crucial for developing targeted interventions.
Purpose of the Study:
- To investigate the association between single nucleotide polymorphisms (SNPs) in the PTPN1 gene and metabolic endophenotypes.
- To explore the relationship between PTPN1 gene variations and insulin sensitivity.
- To identify potential genetic markers for metabolic health.
Main Methods:
- A population-based cross-sectional study involving 382 Dutch Caucasian men aged 40-80 years.
- Genotyping and analysis of four tag SNPs within the PTPN1 gene.
- Statistical analysis to assess associations between PTPN1 SNPs and metabolic parameters.
Main Results:
- Minor alleles of three PTPN1 SNPs (rs6067484, rs6020611, rs1060402) were associated with elevated total and LDL cholesterol in men with BMI < 26 kg/m2.
- The rs3487348 T allele showed a trend towards a more favorable cholesterol profile in men with BMI < 26 kg/m2.
- Haplotypes comprising these alleles showed borderline significant associations with higher LDL and total cholesterol in leaner men.
Conclusions:
- SNPs within the PTPN1 gene are associated with variations in total plasma and LDL cholesterol levels.
- These findings highlight the role of PTPN1 in lipid metabolism.
- Further research is warranted to elucidate the functional mechanisms underlying these associations.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...